Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Refine Results

Despite significant annual variation in research funding and global funding totals that fall far short of the field’s reported needs, the global market in tuberculosis (TB) diagnostics and treatments is expected to grow at a compound annual growth rate (CAGR) of 4.2% by 2025. That’s good news as we acknowledge another World TB Day—and another year dedicated to “Uniting to End TB”. Some of this anticipated growth can be attributed to the increase in funding partnerships enabling smoother international collaboration and cohesive approaches to research. By uniting to set goals for drug and diagnostics development—and redirecting efforts when certain avenues of research  do not provide the... Read More

When most people think of emerging threats to public health, tuberculosis (TB) is unlikely to rise to the forefront of their minds. After all, TB has a long history and has been a well-known global public health challenge for more than a century. But it’s back on the list of emerging health threats due to its change in nature. TB is now increasingly drug resistant, and resistant strains of the disease are spreading quickly, making the infection harder to treat. That’s why multi drug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB) can also be given the reputation of a “superbug”.  As we know, World Tuberculosis Day commemorates the day in 1882 when Dr Robert Koch astounded the... Read More

In 2015 the China Food and Drug Administration (CFDA) ordered companies responsible for 1600+ new drug applications in China to conduct a “self-examination on the authenticity, integrity and compliance of clinical trial data”. Of those 1600+ drug applications approximately 1,100 applications were voluntarily withdrawn. From a recent interview conducted with an official from the department of drug and cosmetics registration of CFDA, it was learned that some of the data were for nonconformance to the Good Clinical Practices (which could affect the accuracy of the clinical trial results), some were for data incompleteness (which could not be traced back, and were insufficient to demonstrate... Read More